ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
ANI’s Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg are the generic version of the Reference Listed Drug (RLD) Compazine® and were developed in technical collaboration with
“We are pleased to bring Prochlorperazine, another limited competition product to the market and provide customers and patients access to high quality generics,” stated
"In keeping with our mission of providing affordable, high quality options for patients; we are pleased to partner with ANI on the launch of this limited competition product,” stated Dr. Jagadeesh Rangisetty, Chief Executive Officer of Biophore.
About ANI
About
Biophore, an established pharmaceutical company, is engaged in the development and manufacturing of niche, high quality pharmaceutical products for the generic industry. Since its inception in 2007, Biophore has emerged as a trusted partner for niche and complex products in the generic industry across US,
Forward-Looking Statements
To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the Company’s generic pipeline, other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.
Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; competition from other products; acquisitions; contract manufacturing arrangements; delays or failure in obtaining and maintaining product approval from the
More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the
All brand names listed are the registered trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005136/en/
Investor Relations:
T: 212-452-2793
E: lwilson@insitecony.com
Media Contact:
T: 817-807-8044
E: Faith.pomeroyward@anipharmaceuticals.com
Source: